1. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., Naidu S.S., Nishimura R.A., Ommen S.R., Rakowski H., Seidman C.E., Towbin J.A., Udelson J.E., Yancy C.W., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. American Association for Thoracic Surgery. American Society of Echocardiography. American Society of Nuclear Cardiology. Heart Failure Society of America. Heart Rhythm Society. Society for Cardiovascular Angiography and Interventions. Society of Thoracic Surgeons 2011 accf/aha guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2011;124(24):e783–e831. doi: 10.1161/CIR.0b013e318223e2bd. [PubMed] [CrossRef] [Google Scholar]
2. Elliott PM, Anastasakis A, Authors/Task Force m 2014 esc guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (esc). . Eur Heart J . 2014;35 (39 ):2733–79. [PubMed] [Google Scholar]
3. Bos J.M., Will M.L., Gersh B.J., Kruisselbrink T.M., Ommen S.R., Ackerman M.J. Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy. Mayo Clin. Proc. 2014;89(6):727–737. doi: 10.1016/j.mayocp.2014.01.025. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Lopes L.R., Rahman M.S., Elliott P.M. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99(24):1800–1811. doi: 10.1136/heartjnl-2013-303939. [PubMed] [CrossRef] [Google Scholar]
5. Lopes L.R., Zekavati A., Syrris P., Hubank M., Giambartolomei C., Dalageorgou C., Jenkins S., McKenna W., Plagnol V., Elliott P.M., Uk10k Consortium Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J. Med. Genet. 2013;50(4):228–239. doi: 10.1136/jmedgenet-2012-101270. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. Olivotto I., Girolami F., Ackerman M.J., Nistri S., Bos J.M., Zachara E., Ommen S.R., Theis J.L., Vaubel R.A., Re F., Armentano C., Poggesi C., Torricelli F., Cecchi F. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin. Proc. 2008;83(6):630–638. doi: 10.1016/S0025-6196(11)60890-2. [PubMed] [CrossRef] [Google Scholar]
7. Van Driest S.L., Ellsworth E.G., Ommen S.R., Tajik A.J., Gersh B.J., Ackerman M.J. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation. 2003;108(4):445–451. doi: 10.1161/01.CIR.0000080896.52003.DF. [PubMed] [CrossRef] [Google Scholar]
8. Arad M., Maron B.J., Gorham J.M., Johnson W.H., Jr, Saul J.P., Perez-Atayde A.R., Spirito P., Wright G.B., Kanter R.J., Seidman C.E., Seidman J.G. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N. Engl. J. Med. 2005;352(4):362–372. doi: 10.1056/NEJMoa033349. [PubMed] [CrossRef] [Google Scholar]
9. Shirani J., Pick R., Roberts W.C., Maron B.J. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J. Am. Coll. Cardiol. 2000;35(1):36–44. doi: 10.1016/S0735-1097(99)00492-1. [PubMed] [CrossRef] [Google Scholar]
10. Geske J.B., Sorajja P., Nishimura R.A., Ommen S.R. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation. 2007;116(23):2702–2708. doi: 10.1161/CIRCULATIONAHA.107.698985. [PubMed] [CrossRef] [Google Scholar]
11. Shah A., Duncan K., Winson G., Chaudhry F.A., Sherrid M.V. Severe symptoms in mid and apical hypertrophic cardiomyopathy. Echocardiography. 2009;26(8):922–933. doi: 10.1111/j.1540-8175.2009.00905.x. [PubMed] [CrossRef] [Google Scholar]
12. Lele S.S., Thomson H.L., Seo H., Belenkie I., McKenna W.J., Frenneaux M.P. Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics. Circulation. 1995;92(10):2886–2894. doi: 10.1161/01.CIR.92.10.2886. [PubMed] [CrossRef] [Google Scholar]
13. Nishimura R.A., Schwartz R.S., Holmes D.R., Jr, Tajik A.J. Failure of calcium channel blockers to improve ventricular relaxation in humans. J. Am. Coll. Cardiol. 1993;21(1):182–188. doi: 10.1016/0735-1097(93)90735-J. [PubMed] [CrossRef] [Google Scholar]
14. Kass D.A., Wolff M.R., Ting C.T., Liu C.P., Chang M.S., Lawrence W., Maughan W.L. Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes. Ann. Intern. Med. 1993;119(6):466–473. doi: 10.7326/0003-4819-119-6-199309150-00004. [PubMed] [CrossRef] [Google Scholar]
15. Matsubara H., Nakatani S., Nagata S., Ishikura F., Katagiri Y., Ohe T., Miyatake K. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 1995;26(3):768–775. doi: 10.1016/0735-1097(95)00229-W. [PubMed] [CrossRef] [Google Scholar]
16. Maron B.J., Wolfson J.K., Epstein S.E., Roberts W.C. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1986;8(3):545–557. doi: 10.1016/S0735-1097(86)80181-4. [PubMed] [CrossRef] [Google Scholar]
17. Maron B.J., Epstein S.E., Roberts W.C. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am. J. Cardiol. 1979;43(6):1086–1102. doi: 10.1016/0002-9149(79)90139-5. [PubMed] [CrossRef] [Google Scholar]
18. Maron M.S., Olivotto I., Zenovich A.G., Link M.S., Pandian N.G., Kuvin J.T., Nistri S., Cecchi F., Udelson J.E., Maron B.J. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–2239. doi: 10.1161/CIRCULATIONAHA.106.644682. [PubMed] [CrossRef] [Google Scholar]
19. Joshi S., Patel U.K., Yao S.S., Castenada V., Isambert A., Winson G., Chaudhry F.A., Sherrid M.V. Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. J. Am. Soc. Echocardiogr. 2011;24(1):75–82. doi: 10.1016/j.echo.2010.10.006. [PubMed] [CrossRef] [Google Scholar]
20. Feiner E., Arabadjian M., Winson G., Kim B., Chaudhry F., Sherrid M.V. Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2013;61(24):2487–2488. doi: 10.1016/j.jacc.2013.02.079. [PubMed] [CrossRef] [Google Scholar]
21. Alhaj E.K., Kim B., Cantales D., Uretsky S., Chaudhry F.A., Sherrid M.V. Symptomatic exercise-induced left ventricular outflow tract obstruction without left ventricular hypertrophy. J. Am. Soc. Echocardiogr. 2013;26(5):556–565. doi: 10.1016/j.echo.2013.02.007. [PubMed] [CrossRef] [Google Scholar]
22. Shah J.S., Esteban M.T., Thaman R., Sharma R., Mist B., Pantazis A., Ward D., Kohli S.K., Page S.P., Demetrescu C., Sevdalis E., Keren A., Pellerin D., McKenna W.J., Elliott P.M. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94(10):1288–1294. doi: 10.1136/hrt.2007.126003. [PubMed] [CrossRef] [Google Scholar]
23. Argulian E., Chaudhry F.A. Stress testing in patients with hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 2012;54(6):477–482. doi: 10.1016/j.pcad.2012.04.001. [PubMed] [CrossRef] [Google Scholar]
24. Sherrid M.V., Arabadjian M. Echocardiography to individualize treatment for hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 2012;54(6):461–476. doi: 10.1016/j.pcad.2012.04.007. [PubMed] [CrossRef] [Google Scholar]
25. Halpern D.G., Sherrid M.V. Echocardiography in hypertrophic cardiomyopathy. Comprehensive Textbook of Echocardiography; 2013. pp. 1348–1368. [Google Scholar]
26. Elesber A., Nishimura R.A., Rihal C.S., Ommen S.R., Schaff H.V., Holmes D.R., Jr Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2008;101(4):516–520. doi: 10.1016/j.amjcard.2007.09.111. [PubMed] [CrossRef] [Google Scholar]
27. Cohen L.S., Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35(5):847–851. doi: 10.1161/01.CIR.35.5.847. [PubMed] [CrossRef] [Google Scholar]
28. Ro R., Halpern D., Sahn D.J., Homel P., Arabadjian M., Lopresto C., Sherrid M.V. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular flow and the mitral valve. J. Am. Coll. Cardiol. 2014;64(19):1984–1995. doi: 10.1016/j.jacc.2014.04.090. [PubMed] [CrossRef] [Google Scholar]
29. Sherrid M.V., Chu C.K., Delia E., Mogtader A., Dwyer E.M., Jr An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993;22(3):816–825. doi: 10.1016/0735-1097(93)90196-8. [PubMed] [CrossRef] [Google Scholar]
30. Sherrid M.V., Gunsburg D.Z., Moldenhauer S., Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2000;36(4):1344–1354. doi: 10.1016/S0735-1097(00)00830-5. [PubMed] [CrossRef] [Google Scholar]
31. Sherrid M.V., Pearle G., Gunsburg D.Z. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 1998;97(1):41–47. doi: 10.1161/01.CIR.97.1.41. [PubMed] [CrossRef] [Google Scholar]
32. Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N. Engl. J. Med. 1982;307(16):997–999. doi: 10.1056/NEJM198210143071607. [PubMed] [CrossRef] [Google Scholar]
33. Sherrid M., Delia E., Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 1988;62(16):1085–1088. doi: 10.1016/0002-9149(88)90553-X. [PubMed] [CrossRef] [Google Scholar]
34. Flamm M.D., Harrison D.C., Hancock E.W. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation. 1968;38(5):846–858. doi: 10.1161/01.CIR.38.5.846. [PubMed] [CrossRef] [Google Scholar]
35. Nistri S., Olivotto I., Maron M.S., Ferrantini C., Coppini R., Grifoni C., Baldini K., Sgalambro A., Cecchi F., Maron B.J. β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2012;110(5):715–719. doi: 10.1016/j.amjcard.2012.04.051. [PubMed] [CrossRef] [Google Scholar]
36. Baker J.G. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br. J. Pharmacol. 2005;144(3):317–322. doi: 10.1038/sj.bjp.0706048. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
37. Epstein S.E., Rosing D.R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64(3):437–441. doi: 10.1161/01.CIR.64.3.437. [PubMed] [CrossRef] [Google Scholar]
38. Ball W., Ivanov J., Rakowski H., Wigle E.D., Linghorne M., Ralph-Edwards A., Williams W.G., Schwartz L., Guttman A., Woo A. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J. Am. Coll. Cardiol. 2011;58(22):2313–2321. doi: 10.1016/j.jacc.2011.08.040. [PubMed] [CrossRef] [Google Scholar]
39. Sherrid M.V., Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog. Cardiovasc. Dis. 2012;54(6):483–492. doi: 10.1016/j.pcad.2012.04.003. [PubMed] [CrossRef] [Google Scholar]
40. Pollick C. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. Am. J. Cardiol. 1988;62(17):1252–1255. doi: 10.1016/0002-9149(88)90269-X. [PubMed] [CrossRef] [Google Scholar]
41. Pollick C., Giacomini K.M., Blaschke T.F., Nelson W.L., Turner-Tamiyasu K., Briskin V., Popp R.L. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Circulation. 1982;66(2):447–453. doi: 10.1161/01.CIR.66.2.447. [PubMed] [CrossRef] [Google Scholar]
42. Sherrid M.V., Barac I., McKenna W.J., Elliott P.M., Dickie S., Chojnowska L., Casey S., Maron B.J. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005;45(8):1251–1258. doi: 10.1016/j.jacc.2005.01.012. [PubMed] [CrossRef] [Google Scholar]
43. Sherrid M.V., Shetty A., Winson G., Kim B., Musat D., Alviar C.L., Homel P., Balaram S.K., Swistel D.G. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail. 2013;6(4):694–702. doi: 10.1161/CIRCHEARTFAILURE.112.000122. [PubMed] [CrossRef] [Google Scholar]
44. Kajimoto K., Imai T., Minami Y., Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am. J. Cardiol. 2010;106(9):1307–1312. doi: 10.1016/j.amjcard.2010.06.059. [PubMed] [CrossRef] [Google Scholar]
45. Kimball B.P., Bui S., Wigle E.D. Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy. Am. Heart J. 1993;125(6):1691–1697. doi: 10.1016/0002-8703(93)90760-7. [PubMed] [CrossRef] [Google Scholar]
46. Teichman S.L., Ferrick A., Kim S.G., Matos J.A., Waspe L.E., Fisher J.D. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J. Am. Coll. Cardiol. 1987;10(3):633–641. doi: 10.1016/S0735-1097(87)80207-3. [PubMed] [CrossRef] [Google Scholar]
47. Fifer M.A., Vlahakes G.J. Management of symptoms in hypertrophic cardiomyopathy. Circulation. 2008;117(3):429–439. doi: 10.1161/CIRCULATIONAHA.107.694158. [PubMed] [CrossRef] [Google Scholar]
48. Balaram SK, Ross RE, Sherrid MV, et al. Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. 2012. [PubMed] [CrossRef]
49. Scirica B.M., Morrow D.A., Hod H., Murphy S.A., Belardinelli L., Hedgepeth C.M., Molhoek P., Verheugt F.W., Gersh B.J., McCabe C.H., Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647–1652. doi: 10.1161/CIRCULATIONAHA.107.724880. [PubMed] [CrossRef] [Google Scholar]
50. Argulian E., Messerli F.H., Aziz E.F., Winson G., Agarwal V., Kaddaha F., Kim B., Sherrid M.V. Antihypertensive therapy in hypertrophic cardiomyopathy. Am. J. Cardiol. 2013;111(7):1040–1045. doi: 10.1016/j.amjcard.2012.12.026. [PubMed] [CrossRef] [Google Scholar]
51. Udelson J.E., Bonow R.O., O’Gara P.T., Maron B.J., Van Lingen A., Bacharach S.L., Epstein S.E. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052–1060. doi: 10.1161/01.CIR.79.5.1052. [PubMed] [CrossRef] [Google Scholar]
52. Harris K.M., Spirito P., Maron M.S., Zenovich A.G., Formisano F., Lesser J.R., Mackey-Bojack S., Manning W.J., Udelson J.E., Maron B.J. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216–225. doi: 10.1161/CIRCULATIONAHA.105.583500. [PubMed] [CrossRef] [Google Scholar]
53. Thaman R., Gimeno J.R., Murphy R.T., Kubo T., Sachdev B., Mogensen J., Elliott P.M., McKenna W.J. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005;91(7):920–925. doi: 10.1136/hrt.2003.031161. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Kato T.S., Takayama H., Yoshizawa S., Marboe C., Schulze P.C., Farr M., Naka Y., Mancini D., Maurer M.S. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2012;110(4):568–574. doi: 10.1016/j.amjcard.2012.04.030. [PubMed] [CrossRef] [Google Scholar]
55. Spoladore R., Maron M.S., D’Amato R., Camici P.G., Olivotto I. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur. Heart J. 2012;33(14):1724–1733. doi: 10.1093/eurheartj/ehs150. [PubMed] [CrossRef] [Google Scholar]
56. Neubauer S. The failing heart--an engine out of fuel. N. Engl. J. Med. 2007;356(11):1140–1151. doi: 10.1056/NEJMra063052. [PubMed] [CrossRef] [Google Scholar]
57. Ingwall J.S., Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ. Res. 2004;95(2):135–145. doi: 10.1161/01.RES.0000137170.41939.d9. [PubMed] [CrossRef] [Google Scholar]
58. Knaapen P., Germans T., Knuuti J., Paulus W.J., Dijkmans P.A., Allaart C.P., Lammertsma A.A., Visser F.C. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation. 2007;115(7):918–927. doi: 10.1161/CIRCULATIONAHA.106.660639. [PubMed] [CrossRef] [Google Scholar]
59. Ashrafian H., Frenneaux M.P., Opie L.H. Metabolic mechanisms in heart failure. Circulation. 2007;116(4):434–448. doi: 10.1161/CIRCULATIONAHA.107.702795. [PubMed] [CrossRef] [Google Scholar]
60. Abozguia K., Elliott P., McKenna W., Phan T.T., Nallur-Shivu G., Ahmed I., Maher A.R., Kaur K., Taylor J., Henning A., Ashrafian H., Watkins H., Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562–1569. doi: 10.1161/CIRCULATIONAHA.109.934059. [PubMed] [CrossRef] [Google Scholar]
61. Sherrid M.V., Gunsburg D.Z., Pearle G. Mid-systolic drop in left ventricular ejection velocity in obstructive hypertrophic cardiomyopathy--the lobster claw abnormality. J. Am. Soc. Echocardiogr. 1997;10(7):707–712. doi: 10.1016/S0894-7317(97)70112-3. [PubMed] [CrossRef] [Google Scholar]
62. Barac I., Upadya S., Pilchik R., Winson G., Passick M., Chaudhry F.A., Sherrid M.V. Effect of obstruction on longitudinal left ventricular shortening in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2007;49(11):1203–1211. doi: 10.1016/j.jacc.2006.10.070. [PubMed] [CrossRef] [Google Scholar]
63. Sherrid M.V., Balaran S.K., Korzeniecki E., Chaudhry F.A., Swistel D.G. Reversal of acute systolic dysfunction and cardiogenic shock in hypertrophic cardiomyopathy by surgical relief of obstruction. Echocardiography. 2011;28(9):E174–E179. doi: 10.1111/j.1540-8175.2011.01459.x. [PubMed] [CrossRef] [Google Scholar]
64. Sherrid M.V., Wever-Pinzon O., Shah A., Chaudhry F.A. Reflections of inflections in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2009;54(3):212–219. doi: 10.1016/j.jacc.2009.03.052. [PubMed] [CrossRef] [Google Scholar]
65. Jeffrey F.M., Alvarez L., Diczku V., Sherry A.D., Malloy C.R. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J. Cardiovasc. Pharmacol. 1995;25(3):469–472. doi: 10.1097/00005344-199503000-00018. [PubMed] [CrossRef] [Google Scholar]
66. Korvald C., Elvenes O.P., Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am. J. Physiol. Heart Circ. Physiol. 2000;278(4):H1345–H1351. [PubMed] [Google Scholar]
67. Ashrafian H., Horowitz J.D., Frenneaux M.P. Perhexiline. Cardiovasc. Drug Rev. 2007;25(1):76–97. doi: 10.1111/j.1527-3466.2007.00006.x. [PubMed] [CrossRef] [Google Scholar]
68. Lee L., Campbell R., Scheuermann-Freestone M., Taylor R., Gunaruwan P., Williams L., Ashrafian H., Horowitz J., Fraser A.G., Clarke K., Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112(21):3280–3288. doi: 10.1161/CIRCULATIONAHA.105.551457. [PubMed] [CrossRef] [Google Scholar]
69. Horowitz J.D., Button I.K., Wing L. Is perhexiline essential for the optimal management of angina pectoris? Aust. N. Z. J. Med. 1995;25(2):111–113. doi: 10.1111/j.1445-5994.1995.tb02820.x. [PubMed] [CrossRef] [Google Scholar]
70. Horowitz J.D., Sia S.T., Macdonald P.S., Goble A.J., Louis W.J. Perhexiline maleate treatment for severe angina pectoris--correlations with pharmacokinetics. Int. J. Cardiol. 1986;13(2):219–229. doi: 10.1016/0167-5273(86)90146-4. [PubMed] [CrossRef] [Google Scholar]
71. Singlas E., Goujet M.A., Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur. J. Clin. Pharmacol. 1978;14(3):195–201. doi: 10.1007/BF02089960. [PubMed] [CrossRef] [Google Scholar]
72. Evans W.E., Relling M.V., Rahman A., McLeod H.L., Scott E.P., Lin J.S. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest. 1993;91(5):2150–2154. doi: 10.1172/JCI116441. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
73. Gardiner S.J., Begg E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 2006;58(3):521–590. doi: 10.1124/pr.58.3.6. [PubMed] [CrossRef] [Google Scholar]
74. Cole P.L., Beamer A.D., McGowan N., Cantillon C.O., Benfell K., Kelly R.A., Hartley L.H., Smith T.W., Antman E.M. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990;81(4):1260–1270. doi: 10.1161/01.CIR.81.4.1260. [PubMed] [CrossRef] [Google Scholar]
75. Alderman C.P., Hundertmark J.D., Soetratma T.W. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust. N. Z. J. Psychiatry. 1997;31(4):601–603. doi: 10.3109/00048679709065084. [PubMed] [CrossRef] [Google Scholar]
76. Coppini R., Ferrantini C., Yao L., Fan P., Del Lungo M., Stillitano F., Sartiani L., Tosi B., Suffredini S., Tesi C., Yacoub M., Olivotto I., Belardinelli L., Poggesi C., Cerbai E., Mugelli A. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127(5):575–584. doi: 10.1161/CIRCULATIONAHA.112.134932. [PubMed] [CrossRef] [Google Scholar]
77. Antzelevitch C., Belardinelli L., Zygmunt A.C., Burashnikov A., Di Diego J.M., Fish J.M., Cordeiro J.M., Thomas G. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904–910. doi: 10.1161/01.CIR.0000139333.83620.5D. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
78. Teekakirikul P., Eminaga S., Toka O., Alcalai R., Wang L., Wakimoto H., Nayor M., Konno T., Gorham J.M., Wolf C.M., Kim J.B., Schmitt J.P., Molkentin J.D., Norris R.A., Tager A.M., Hoffman S.R., Markwald R.R., Seidman C.E., Seidman J.G. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J. Clin. Invest. 2010;120(10):3520–3529. doi: 10.1172/JCI42028. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
79. Lim D.S., Lutucuta S., Bachireddy P., Youker K., Evans A., Entman M., Roberts R., Marian A.J. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103(6):789–791. doi: 10.1161/01.CIR.103.6.789. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
80. Shimada Y.J., Passeri J.J., Baggish A.L., O’Callaghan C., Lowry P.A., Yannekis G., Abbara S., Ghoshhajra B.B., Rothman R.D., Ho C.Y., Januzzi J.L., Seidman C.E., Fifer M.A. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. JACC Heart Fail. 2013;1(6):480–487. doi: 10.1016/j.jchf.2013.09.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
81. Ho C. Vanish: Valsartan for attenuating disease evolution in early sarcomeric HCM. 2014. 2014. [PMC free article] [PubMed]
82. Maron M., Kerur B., Chan R.H., et al. Can spironolactone mitigate myocardial fibrosis and alter suddendeath risk and heart failure symptoms in patients with hypertrophic cardiomyopathy? A prospective, randomized trial. Circulation. 2013;128:A16910. [Google Scholar]
Page 2
Adverse consequences of mitral-septal contact.
|